Amgen, UCB commence CDP7851/AMG 785 Stage 3 trial in postmenopausal osteoporosis UCB and Amgen announced today the start of their sclerostin antibody Stage 3 clinical trial plan for the treatment of postmenopausal osteoporosis. We anticipate dealing with UCB on the CDP7851/AMG 785 Phase 3 system, said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. Despite available osteoporosis therapies, there continues to be a substantial need for additional treatment options that form fresh bone in women diagnosed with postmenopausal osteoporosis.As the incidence of side effects decreases, the costs associated with treating those side effects declines also. Real-time tracking may permit a clinically significant reduction in side effects, thereby raising treatment tolerance and enabling delivery of the entire radiation dose for far better treatment. ‘The initiation of this clinical study is an important milestone in our vision to leverage Calypso’s technology to extra body sites where radiation delivery is severely hampered by the inability to manage tumor movement,’ said Edward Vertatschitsch, Interim CEO of Calypso Medical. ‘We are really excited to be as of this juncture where we are becoming a member of our years of advancement effort with lung cancers radiotherapy, a frontier with an unmet clinical want.